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Abstract
Background: In pancreatitis, total pancreatectomy (TP) is an effective treatment for refractory pain.
Islet cell auto-transplantation (IAT) may mitigate resulting endocrinopathy. Short-term morbidity data for
TP + IAT and comparisons with TP are limited.
Methods: This study, using 2005–2011 National Surgical Quality Improvement Program data, examined
patients with pancreatitis or benign neoplasms. Morbidity after TP alone was compared with that after
TP + IAT.
Results: In 126 patients (40%) undergoing TP and 191 (60%) patients undergoing TP + IAT, the most
common diagnosis was chronic pancreatitis. Benign neoplasms were present in 46 (14%) patients, six of
whom underwent TP + IAT. Patients in the TP + IAT group were younger and had fewer comorbidities than
those in the TP group. Despite this, major morbidity was more frequent after TP + IAT than after TP [n =
79 (41%) versus n = 36 (29%); P = 0.020]. Transfusions were more common after TP + IAT [n = 39 (20%)
versus n = 9 (7%); P = 0.001], as was longer hospitalization (13 days versus 9 days; P < 0.0001). There
was no difference in mortality.
Conclusions: This study is the only comparative, multicentre study of TP and TP + IAT. The TP + IAT
group experienced higher rates of major morbidity and transfusion, and longer hospitalizations. Better
data on the longterm benefits of TP + IAT are needed. In the interim, this study should inform physicians
and patients regarding the perioperative risks of TP + IAT.
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Introduction
In pancreatitis, total pancreatectomy (TP) is an effective treatment
for refractory pain; however, the resulting loss of pancreatic islet
cells results in brittle diabetes with potentially volatile blood
sugars. Islet cell auto-transplantation (IAT) is an attempt to miti-
gate this serious and permanent endocrinopathy resulting from
TP. Whereas pancreatitis is seen and treated worldwide, TP +
IAT is limited to relatively few centres. Physicians and surgeons
who treat refractory pancreatitis must debate whether patients
should be preferentially referred to centres for TP + IAT over TP
alone. Given the infrequency of TP and TP + IAT, data on the
short-term morbidity associated with either procedure are
limited.
The benefits of TP, with or without IAT, include reductions in
chronic pain and narcotic use, and better function. Garcea et al.1
found the proportion of patients using opiates decreased from
90.2% preoperatively to 15.9% at 5 years. However, TP + IAT is an
imperfect solution to post-TP endocrinopathy because many
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patients require insulin in the long term. In a recent meta-analysis
of outcomes after TP + IAT, insulin independence was found to
amount to 27% at 1 year and 21% at 2 years.2
Because TP + IAT is surgically quite different from TP, the
associated risks andmorbidity are unique.A retrospective study of
26 patients demonstrated a morbidity rate of 56% with TP + IAT.3
Another series showed that re-laparotomy was required in 15.9%
of patients and that bleeding was the most common complica-
tion.4 By contrast, series of TP alone have shown morbidity rates
of 36.5–39.0%, and a reoperation rate of 5%.5,6 Despite its poten-
tial benefits, the risks associated with TP + IAT appear to be
greater than those associated with TP alone.
This study employed a nationwide, prospective, clinical data-
base to compare perioperative outcomes in patients undergoing
TP alone with those in patients submitted to TP + IAT. This may
serve to better inform physicians and counsel patients regarding
the risks of referral for TP + IAT.
Materials and methods
Data source and inclusion criteria
This was an observational study using National Surgical Quality
Improvement Program (NSQIP) data for 2005–2011. The NSQIP
database is a surgical outcomes research effort organized by the
American College of Surgeons (ACS). For selected patients, a
specially trained nurse reviewer collects data on preoperative
comorbidities, intraoperative parameters, and 30-day postopera-
tive morbidity and mortality. The database is de-identified and
therefore this study was exempt from the institutional review
board process.
This study examined the primary and all concurrent procedure
fields for current procedural terminology (CPT) codes for eligible
patients. The TP group included any patient with the CPT code
48155, in the absence of any code for IAT. The TP + IAT group
included any patient with the CPT code of 48160. In addition,
patients were included in the TP + IAT group if they had the CPT
code 48155 (total pancreatectomy) and a separate IAT code of
0141T, 0142T, 0143T, G0341, G0342, G0343 or S2102. Only
patients submitted to concurrent IAT, performed in the operating
room, were considered in this analysis. Patients in whom surgery
was deemed emergent or in whom disseminated cancer was
found were excluded. Patients who carried a postoperative diag-
nosis of pancreatitis or benign neoplasm (codes 577*, 211*, 157*
or 171*) were selected. The final population comprised all
patients who underwent elective TP and might have been candi-
dates for IAT.
Data and outcomes
The study examined standard demographic data, postoperative
diagnosis, and the following comorbidities as potential predictors
of outcome: (i) diabetes; (ii) cardiac disease (hypertension,
angina, previous myocardial infarction, cardiac angioplasty or
bypass surgery); (iii) active pulmonary disease (pneumonia and
severe chronic obstructive pulmonary disease), and (iv) nutri-
tional status (weight loss and albumin).
The primary outcome was major morbidity. Major morbidity
was defined as re-intubation, prolonged intubation, pneumonia,
cardiac arrest, myocardial infarction, renal failure requiring dialy-
sis, deep or organ space infection,pulmonary embolus, transfusion
requirement, sepsis, shock, stroke or coma.7 Minor morbidity was
defined as urinary tract or superficial wound infection, deep vein
thrombosis, or creatinine elevated by >2 mg/dl above baseline
without the need for dialysis. The other outcomes examined were
mortality, and cardiac, pulmonary, wound-related, infectious,
hemorrhagic and venous thromboembolic (VTE) morbidity.
Statistical analysis
Mean and median values were used to describe continuous data.
Discrete variables were displayed as frequencies. For bivariable
analyses, two-tailed t-tests and Mann–Whitney U-tests were used
to compare continuous data as appropriate according to the dis-
tribution of the data; Fisher’s exact or chi-squared tests were used
for categorical variables. Multivariable regression analysis was
employed to attempt to adjust for confounders. Separate
multivariable models for regression analyses of major and minor
morbidity were derived. A priori, age and American Society of
Anesthesiologists (ASA) class of ≥3 were included as covariables as
a result of their known associations with morbidity and mortality.
Additional eligible covariables were those that: (i) differed
between groups at baseline, and (ii) showed association with the
outcome on univariate analysis. To ensure the most parsimonious
model, eligible covariables were run through a stepwise selection
process and only covariables with a P-value of <0.1 were included
in the final models. The Hosmer–Lemeshow test was used to
check goodness of fit. A predetermined subgroup analysis of only
patients with pancreatitis, excluding patients with a diagnosis of
benign neoplasm (code of 211*), was conducted. All statistical
analysis was performed using stata SE Version 12 (StataCorp LP,
College Station, TX, USA).
Results
Population characteristics
Of 607 patients undergoing eligible TPs, 14 (2%) emergency
patients and 24 (4%) patients with disseminated cancer were
excluded. Patients with a postoperative diagnosis of malignancy
(n = 186), carcinoma in situ (n = 10) or an unknown diagnosis
(n = 56) were excluded. The final study sample consisted of 317
patients, of whom 126 (40%) underwent TP alone and 191 (60%)
underwent TP + IAT. The most common postoperative diagnosis
was chronic pancreatitis (n = 244, 77%). The majority of patients
with benign neoplasms underwent TP and only six of 46 (13%)
patients underwent TP + IAT (P < 0.001). The most common
comorbidities were diabetes (n = 60, 19%) and hypertension (n =
84, 26%).
Patients undergoing TP + IAT were generally healthier
(Table 1). They were younger and had less commonly experienced
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preoperative weight loss of >10% of body weight than patients in
the TP group (Table 1). Although these data are not necessarily
clinically significant,median albumin was higher among TP + IAT
patients compared with TP patients (4.1 g/dl versus 3.9 g/dl; P =
0.011). Hypertension, diabetes and coronary artery disease were
more prevalent among TP patients (P < 0.002).
Outcomes
The primary outcome, major morbidity, occurred in 115 (36%)
patients. These events occurred more frequently in patients
undergoing TP + IAT compared with those submitted to TP alone
[n = 79 (41%) versus n = 36 (29%); P = 0.02]. Multivariable
logistic regression was conducted to adjust for baseline differences
in patient age, preoperative weight loss, hypertension,ASA class of
≥3, and transfusion of ≥2 units of red blood cells (RBCs). The
model showed that TP + IAT was associated with an increase of
96% in the odds of major morbidity [95% confidence interval
(CI) 1.1–3.5; P = 0.020]. However, Hosmer–Lemeshow testing of
the regression showed poor model fit (P = 0.0002), which suggests
that this model may not explain the outcome well. Despite a
narrow confidence interval and statistical significance, the
adjusted analysis should be interpreted with this caveat.
The two groups experienced the same incidence of minor
complications (n = 60, 19%). The multivariable model included
the following covariables: age; ASA class of ≥3; transfusion of ≥2
units of RBCs, and diabetes. Performance of TP + IAT was not
associated with increased odds of minor morbidity on logistic
regression [odds ratio (OR) 0.98, 95% CI 0.5–1.9; P = 0.950].
Hosmer–Lemeshow testing showed goodness of fit (P = 0.609).
There was a trend towards higher overall morbidity in the TP +
IAT group. Although the difference was not statistically signifi-
cant, 48 (38%) patients in the TP group and 93 (49%) patients in
the TP + IAT group suffered some morbidity (P = 0.063).
Analysis of the secondary outcomes showed no difference in
mortality, surgical site infection or shock (Table 2). Myocardial
infarction and cardiac arrest were sufficiently rare in both groups
as to obviate valid statistical comparison. Postoperative pneumo-
nia, septic andVTE complications were slightly higher in the TP +
IAT group, but the differences were not statistically significant
(P > 0.05). Transfusions were substantially more frequent after
TP + IAT [n = 39 (20%) versus n = 9 (7%); P = 0.001]. Patients
who underwent TP + IAT required longer hospitalizations (13
days versus 9 days; P < 0.0001).
Subset analysis
The predetermined subset excluded patients undergoing resection
for benign tumours in order to focus on those with the best
established indication for TP + IAT, namely, pancreatitis. As
Table 1 Characteristics of the study population (n = 317)
TP group TP + IAT group P-value
n = 126 (40%) n = 191 (60%)
Age, years, median (range) 54 (18–78) 40 (18–70) < 0.0001
Male, n (%) 51 (40%) 48 (25%) 0.006
Active tobacco use, n (%) 42 (33%) 60 (31%) 0.720
Alcohol abuse, n (%) 3 (2%) 0 0.059
Weight loss of > 10% in 6 months, n (%) 15 (12%) 11 (6%) 0.051
Albumin, g/dl, median (range) 3.9 (1.5–5.1) 4.1 (1.9–5.4) 0.011
Comorbidities, n (%)
Chronic pulmonary disease 5 (4%) 3 (2%) 0.183
Hypertension 59 (47%) 25 (13%) < 0.001
Diabetes 42 (33%) 18 (9%) < 0.001
Coronary artery disease 13 (10%) 4 (2%) 0.002
ASA class of ≥ 3, n (%) 93 (74%) 121 (63%) 0.052
Diagnosis, n (%)
Chronic pancreatitis 73 (58%) 171 (90%) < 0.001
Acute pancreatitis 13 (10%) 14 (7%)
Benign neoplasm 40 (32%) 6 (3%) < 0.001
Concurrent procedure, n (%)
Splenectomy 55 (44%) 146 (76%) < 0.001
Gastrectomy 10 (8%) 0 < 0.001
Lymphadenectomy 3 (2%) 2 (1%) 0.351
Operative time, min, median (range) 310 (75–1140) 530 (370–1007) < 0.0001
TP, total pancreatectomy; IAT, islet cell auto-transplantation; ASA, American Society of Anesthesiologists.
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expected based on the findings shown in Table 1, this reduced the
TP group in size (n = 86) to a greater extent than it did the TP +
IAT group (n = 185). The study findings were unchanged; TP +
IAT was associated with increased rates of major morbidity (P =
0.036) and transfusion (P = 0.005) (Table 3). This group con-
tinued to have a significantly longer hospital stay (P = 0.006).
Discussion
The pain caused by chronic pancreatitis is associated with sub-
stantial reductions in quality of life. Although it is not a panacea,
TP can provide pain relief. Studies showmarked improvements in
physical and mental domains on instruments measuring quality
of life, as well as decreased narcotic use.8–10 Total pancreatectomy
is reserved for refractory patients because of the risks for postop-
erative diabetes and persistent pain. The combination of TP +
IAT, which is a very different procedure, has implications for
perioperative morbidity.
The present data show a 50% higher rate of major morbidity, a
nearly three-fold rate of transfusion, and a longer length of stay in
patients undergoing TP + IAT compared with those undergoing
TP alone. Differences between the procedures may explain this. To
avoid warm ischaemia to the islet cells during TP + IAT, vascular
ligation is performed later than in TP, and this is likely to increase
blood loss. In addition, major peritoneal haemorrhage is one of
the more common complications after islet cell transplantation.
These factors and the systemic anticoagulation used during TP +
IAT are likely to result in higher perioperative blood loss and
transfusion rates. Although the individual differences are not sta-
tistically significant, higher rates of VTE, pneumonia and sepsis,
when aggregated, are likely to explain the substantially higher
major morbidity in TP + IAT.
Table 2 Postoperative morbidity in the study population (n = 317)
TP group TP + IAT group P-value
n = 126 (40%) n = 191 (60%)
Death, n (%) 3 (2%) 1 (1%) 0.147
Any morbidity, n (%) 48 (38%) 93 (49%) 0.063
Major morbidity, n (%) 36 (29%) 79 (41%) 0.020
Minor morbidity, n (%) 24 (19%) 36 (19%) 0.965
Surgical site infection, n (%) 21 (17%) 33 (17%) 0.887
Venous thromboembolism, n (%) 4 (3%) 11 (6%) 0.289
Pneumonia, n (%) 7 (6%) 20 (10%) 0.125
Re-intubation, n (%) 4 (3%) 7 (4%) 0.815
Failure to wean, n (%) 8 (6%) 12 (6%) 0.981
Transfusion, n (%) 9 (7%) 39 (20%) 0.001
Sepsis, n (%) 16 (13%) 28 (15%) 0.621
Shock, n (%) 3 (2%) 2 (1%) 0.351
LoS, days, median (range) 9 (3–120) 13 (4–195) < 0.0001
TP, total pancreatectomy; IAT, islet cell auto-transplantation; LoS, length of stay.
Table 3 Postoperative morbidity in the subset of patients with pancreatitis only (n = 271)
TP group TP + IAT group P-value
n = 86 (32%) n = 185 (68%)
Death, n (%) 3 (3%) 1 (1%) 0.061
Major, n (%) 24 (28%) 76 (41%) 0.036
Minor, n (%) 19 (22%) 34 (18%) 0.473
Wound, n (%) 13 (15%) 31 (17%) 0.733
Pneumonia, n (%) 6 (7%) 20 (11%) 0.319
VTE, n (%) 4 (5%) 10 (5%) 0.794
Transfusion, n (%) 6 (7%) 38 (21%) 0.005
Sepsis, n (%) 11 (13%) 27 (15%) 0.691
Shock, n (%) 3 (3%) 1 (1%) 0.061
LoS, days, median (range) 10 (3–120) 13 (4–195) 0.006
TP, total pancreatectomy; IAT, islet cell auto-transplantation; VTE, venous thromboembolism; LoS, length of stay.
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Despite higher major morbidity, mortality was not significantly
worse in TP + IAT patients. Selection bias, demonstrated by base-
line differences in patient age and comorbidities, may explain this.
Gusani et al.11 showed that perioperative mortality was predicted
well by a model that included only preoperative risk factors, which
was minimally improved by the addition of further parameters.
Alternatively, TP + IAT is only performed at large institutions that
are likely to have the capacity to rescue patients who experience
major complications.12
Postoperative hepatic insufficiency may explain the longer hos-
pitalizations of TP + IAT patients. Islet transplantation registry
data demonstrate that transient hepatic insufficiency is not
uncommon.13 Portal hypertension or hepatic ischaemia may
occur through the occlusion of portal venules by infused islet cells.
This is invariably self-limited. However, this theory cannot
be tested as the NSQIP does not assess postoperative hepatic
function.
Overall, the findings of the present study are consistent with
data reported in the existing literature. Current series of TP alone
report perioperative morbidity rates of 36.5–39.0%.5,6,14 Similar
series of TP + IAT have shownmorbidity in 58–69% of patients.3,15
This literature also supports the present authors’ conclusion that
TP + IAT may be associated with higher morbidity. The uniform
data collection of the NSQIP across multiple centres allows for the
direct comparison of outcomes between TP alone and TP + IAT.
The indication for TP + IAT has generally been chronic pan-
creatitis. However, there is a small group of patients in whom
benign tumours require TP. In a recent series, patients with pan-
creatic body or neck tumours received IAT.16 These data show that
TP + IAT is performed, albeit rarely, in patients with benign neo-
plasia. However, as the clearest indication for TP + IAT is pancrea-
titis, this group was examined separately. The results of the
subgroup analysis mirrored those in the larger population, which
adds robustness to these findings.
The limitations of the present study arise from the dataset and
the study’s retrospective design. In this study, 60% of patients
underwent TP + IAT, which implies that centres performing this
procedure are over-represented in the NSQIP. However, if the
experience of centres expert in TP + IAT demonstrates higher
morbidity despite the selection of healthier patients, the morbid-
ity attendant on TP + IAT must be higher. In addition to selection
bias, there remains the possibility that patients in whom IAT was
performed after a delay may be miscategorized under the TP
rather than the TP + IAT group.
This study compared the perioperative morbidity associated
with TP + IAT and TP, respectively, but does not support any
comment on the benefits of either treatment. A review of the
current literature demonstrates that IAT may mitigate the severity
of insulin-dependent diabetes, but should not be thought of as
preventing its occurrence. Over time, rates of type 2 diabetes drop
substantially from 46% at 5 years, declining to 10% at 8 years.17
However, even if patients do not have type 2 diabetes, their average
daily insulin use may be lower after TP + IAT than after TP alone.1
Longterm studies demonstrate declining graft function and
increasing insulin use.18 The true benefit of IAT may lie in the
reduction of hypoglycaemic episodes, but these data are rarely
reported.19 This benefit must be set in the context of perioperative
morbidity. Previously, data on the risks of TP + IAT were limited
to single-institution series and did not compare outcomes with
those of TP.
Conclusions
Total pancreatectomy is the last resort for patients whose chronic
pancreatitis has failed to respond to all other treatments. Despite
being effective for symptoms, TP results in endocrinopathy. Sur-
geons considering TP should discuss referral to centres which
perform TP + IAT with patients. However, TP + IAT may only
mitigate endocrinopathy after whole-gland resection. Surgically,
TP + IAT is a very different procedure and data on perioperative
morbidity are limited. This study is the only prospective,
multicentre study to have compared the perioperative outcomes
of TP with those of TP + IAT. These data demonstrate higher rates
of major morbidity and transfusion requirements, and longer
hospitalizations in patients undergoing TP + IAT. In this relatively
rare procedure with significant potential for patient benefit, better
longterm outcomes data and large prospective series demonstrat-
ing perioperative outcomes may improve patient counselling and
surgeon referrals. In the interim, for surgeons performing TP
without IAT, this study should better inform patient discussions
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